Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.
about
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerMaximal testosterone suppression in the management of recurrent and metastatic prostate cancerTestosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerA novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variantsEfficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate CancerExtended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical TrialPharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.Reporting and ideal testosterone levels in men undergoing androgen deprivation for prostate cancer-time for a rethink?Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone.
P2860
Q26744431-37BBEDA3-52BC-4477-9ECE-4DBDB1FBAE86Q26747782-09269C6F-0B32-4118-8257-2EA3BDB428C4Q29994552-99E4A14E-31D0-4041-B05C-D8A45EC583AAQ33803812-FD9EDE05-2D10-4EB3-AC04-4C5DADE9D930Q34104391-BE9D178E-844E-4B9D-B077-8899822558BFQ36087132-94108560-2496-43D9-A4EE-526868A04A60Q37672477-AB038428-5A46-421F-AE36-9F6D6248D2D0Q38570555-EC822CF5-5658-4222-A025-04505FDEF9EFQ38739542-2CA7A93C-7CFD-4FFA-A56A-6AAD887D5479Q39908629-DE72E99C-0725-4444-9ECB-E46681E1D1C5Q42534471-1C550BBD-77F5-4222-9084-3A21D3D95454Q49787745-B62136C7-FA4F-4935-AF0A-FC2C7A12454FQ52572665-1B9F8362-EA37-4DB7-BCDC-BFBF5C2224B3Q52647565-DA169D27-9140-48AB-8EB0-BA96C382CA27Q53762958-3543673A-14BC-4F0D-BAA5-CCF68DE85EF6
P2860
Defining a new testosterone threshold for medical castration: Results from a prospective cohort series.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Defining a new testosterone th ...... m a prospective cohort series.
@en
type
label
Defining a new testosterone th ...... m a prospective cohort series.
@en
prefLabel
Defining a new testosterone th ...... m a prospective cohort series.
@en
P2093
P2860
P356
P1476
Defining a new testosterone th ...... om a prospective cohort series
@en
P2093
Bobby Shayegan
Christopher B Allard
Justin Tong
P2860
P304
P356
10.5489/CUAJ.471
P50
P577
2013-05-01T00:00:00Z